0001) for the SOS cascade (BDNF, SOS1, SOS2, and SYN1), whereas for the AKT cascade (BDNF, AKT1
, AKT2, and AKT3) associations between gene expression and [PM.
As with the other samples in that study, the sequenced amplicons were shown to have multiple artifacts in exons of the AKT1
and BRAF genes.
The study to be published in the Journal of Cellular Biochemistry on November 1, 2009 (Volume 108, pages 832-838 in Issue 4), also found that the combined treatment of AKT1
AO with cytotoxic drugs showed even greater anti-tumor activity in human renal carcinoma cell line.
There were no differences between UPSC and EOS-C in the rates of mutation of APC, ATM, BRAF, and AKT1
Identify the most promising approaches to kinase modulation in cancer and other diseases by examining drug targets including ABL1, EGFR, ERBB2, FLT3, KIT, PDGFRA, PDGFRB, FLT1, FLT4, KDR, JAK2, MET, AKT1
, CDC2, CDK2, AURKA, AURKB, PLK1, FRAP1 and PIK3CA.
We were pleased to find higher incidences of the AKT1
, KRAS, PIK3CA, and TP53 mutations, which suggest potential druggable mutations and areas of research for further therapy development.
The AKT protein family consists of the AKT1
and AKT2 isoforms, which play distinct roles in cell migration.
60) Mutations in AKT1
(v-akt murine thymoma viral oncogene homologue 1) gene, which encodes protein kinase B have been identified in several solid malignancies including breast, colon, and ovarian carcinomas.
Specifically, NGS revealed mutations in the PIK3CA (33%), FBXW7 (14%), and AKT1
(2%) genes, and IHC detected loss of the PTEN protein in 54% of samples, suggesting that agents targeting the PI3-kinase pathway may be useful in tumors harboring these mutations.
Among these are KRAS, HER2/neu, BRAF, NRAS, MEK1, and AKT1
Tumor samples from 288 patients, which had previously been analyzed for KRAS exon 2 mutations, were analyzed in this study for mutations in nine genes: KRAS (exon 3), NRAS, BRAF, PIK3CA, PTEN, AKT1
, EGFR, beta-catenin (CINN1B) and TP53.
INDIANAPOLIS, July 4 /PRNewswire-FirstCall/ -- Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1
in breast, colorectal and ovarian cancers.